BusinessProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher SyndromeBy Nasdaq OMXMay 1, 2017, 11:01 AM UTC
BusinessProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher SyndromeBy Nasdaq OMXMay 1, 2017, 11:01 AM UTC
BusinessProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 PatientsBy Nasdaq OMXApr 27, 2017, 11:03 AM UTC
BusinessProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 PatientsBy Nasdaq OMXApr 27, 2017, 11:03 AM UTC
BusinessProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 PatientsBy Nasdaq OMXApr 27, 2017, 11:03 AM UTC
BusinessProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 PatientsBy Nasdaq OMXApr 27, 2017, 11:02 AM UTC
BusinessProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EUBy Nasdaq OMXApr 3, 2017, 11:02 AM UTC
BusinessProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EUBy Nasdaq OMXApr 3, 2017, 11:02 AM UTC
